Project Grant F30CA310065
Award Date 12/1/26
Completion Date 5/31/30
Dollars Obligated $110K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
- The National Cancer Institute awarded $413,339 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on chimeric antigen receptor (CAR) T-cell therapy for lymphoma treatment. The research aligns T-cell biology with CAR architecture to enhance lymphoma therapy, addressing the limitation that durable responses are achieved in only 35–50% of lymphoma patients currently...
- The National Cancer Institute, within the Department of Health and Human Services, awarded $442,146 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a first-in-class clinical trial of natural killer cell therapy engineered to target intracellular antigens in acute myeloid leukemia and high-risk myelodysplastic syndromes. The funded work develops and tests cord blood-derived, off-the-shelf NK cells...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,920 on March 11, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing) to conduct research on novel multi-targeted therapeutic strategies targeting T-cell lymphomas and their microenvironment. The funded work addresses chemotherapy-resistant T-cell lymphomas, where current treatments produce poor durable responses and clinical trial participation remains standard care. The...
- The National Cancer Institute awarded Weill Medical College of Cornell University $435,827 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop autologous lymph node T cells engineered to overcome treatment-resistant lung cancer. The research addresses the limited effectiveness of adoptive T-cell therapy in solid tumors by utilizing polyclonal cohorts of multipotent T cells derived from tumor-draining lymph nodes rather than peripheral blood. Prior work...
- The National Cancer Institute awarded The Washington University $548,528 under the Cancer Treatment Research program (CFDA 93.395) on September 3, 2026, to enhance CAR-T cell therapy for relapsed or refractory large B cell lymphoma. The recipient will conduct a Phase 1B clinical trial evaluating early and repeated dosing schedules of NT-I7, a long-acting interleukin-7 therapeutic, administered following axicabtagene ciloleucel or lisocabtagene maraleucel infusion in patients with relapsed or...
- The National Cancer Institute awarded The Johns Hopkins University $218,089 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test engineered natural killer cell therapy targeting acute myeloid leukemia. The funded work develops chimeric cytokine receptor (CCR)-engineered NK cells designed to attack AML-associated surface antigens and overcome AML-mediated NK cell suppression. In Aim 1, the recipient will engineer NK cells to express dual interleukin...
- The National Cancer Institute awarded The Johns Hopkins University $387,178 on August 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop lipid nanoparticle-based immunotherapy strategies for in-situ generation of dual T cell receptor/chimeric antigen receptor T cells targeting cancer. The award funds research to address the barrier of scalable systems for delivering genetic material to CD4+ T cells. The project leverages a high-throughput mRNA lipid...
- The National Cancer Institute awarded the Regents of the University of Michigan $401,115 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate novel therapeutic strategies targeting the enhancer landscape in high-risk T-cell lymphomas. The research addresses T-cell lymphomas driven by the transcription factor GATA-3, which remain largely incurable with existing therapies. The project characterizes GATA-3-dependent enhancers and evaluates P300/CBP bromodomain...
- The National Cancer Institute awarded Mayo Clinic $685,116 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of interleukin-5 (IL-5) in chimeric antigen receptor T cell immunotherapy for cancer. The project addresses treatment failure and toxicity in CAR T cell therapy, which has achieved FDA approval in relapsed or refractory hematological cancers but shows high relapse rates within two years and significant adverse effects including...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $387,156 on August 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to advance TGF-beta-resistant CAR-NK cell therapy for acute myeloid leukemia. The work targets relapsed/refractory AML through a clinical trial using cord blood-derived CAR-NK cells engineered to express a truncated human CD27, CD28 costimulatory domain, CD3-zeta signaling domain, IL-15, and an inducible caspase-9 safety...